Latanoprostene bunod ophthalmic solution, also known by its brand name Vyzulta, is a prostaglandin. This eye drop medication is used to treat conditions related to high pressure in the eye, such as glaucoma. Vyzulta (latanoprostene bunod) is approved for people 17 years of age and older. It's given as a drop into the affected eye(s) once daily in the evening. Vyzulta (latanoprostene bunod) bottles should be refrigerated, but they can be stored at room temperature for up to 8 weeks after opening. Side effects include eye redness and eye pain.
Lowering pressure in the eye in people with ocular hypertension (high pressure in the eye) or open-angle glaucoma
Vyzulta (latanoprostene bunod) is a prostaglandin. It lowers eye pressure by draining fluid from your eye.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report to your care team if they continue or are bothersome):
Might work better at lowering eye pressure than beta-blocker eye drops
Once-a-day eye drop
Can use with other eye pressure-lowering medications
Can change the color of your eyes
No lower-cost generic available; brand-name medication only
Not recommended for children age 16 and younger because of possible permanent changes to eye color with long-term use
Set reminders on your calendar for your appointments with your optometrist or ophthalmologist. You'll need regular eye exams so that your eye specialist can check how well Vyzulta (latanoprostene bunod) is working for you. They'll also check for side effects related to the eyes.
If you wear soft contact lenses, take them out each time before you use Vyzulta (latanoprostene bunod). The eye drops contain a preservative called benzalkonium chloride that can damage your contacts. Wait 15 minutes after you use the eye drops to put your contacts back in.
Be sure to review how to use Vyzulta (latanoprostene bunod) eye drops. Ask your eye specialist or pharmacist if you have any questions about using the eye drops.
Wash your hands before you put Vyzulta (latanoprostene bunod) drops in your eye. After placing a drop in the eye, close your eye and press one finger to the inner corner of your eye by the nose and press lightly for a minute. This helps make sure your eye absorbs the medication.
Keep the bottle and tip of Vyzulta (latanoprostene bunod) clean. Cap and tightly close the Vyzulta (latanoprostene bunod) bottle when you're not using it. And don't let the dropper tip touch your eye or any other surface, and don't touch the tip with your hands. Otherwise, the medication can get contaminated with germs, which can lead to eye infections if you use the eye drops afterwards.
You might need more than one kind of eye drop to help lower your eye pressure. If you're using other eye medications in the evening at the same time as Vyzulta (latanoprostene bunod), wait 5 minutes between each medication so that you eye can fully absorb each one.
If you forget to use Vyzulta (latanoprostene bunod) one night, just skip the dose. Use the eye drops the next evening. Don't double up to make up for the missed dose.
Vyzulta (latanoprostene bunod) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Vyzulta (latanoprostene bunod) can darken the color of your eyes, eyelashes, and eyelids. This change in color happens because the medication raises the levels of melanin in your eyes. Melanin is a protein that's responsible for the color of certain parts of your eyes.
The change in color might not be noticeable until after a few months or years of using Vyzulta (latanoprostene bunod). Color changes in the iris (the circular colored part of your eye) are most likely permanent. Your eyelashes and the skin around your eyes might also become darker, but this usually goes away after you stop using the medication. These side effects aren't known to be harmful, but it's best to regularly check in with your prescriber so they can make sure your eyes stay healthy.
Vyzulta (latanoprostene bunod) can make your eyelashes grow in length or thickness over time. It can also make you grow more eyelashes. These changes are typically reversible when you stop the medication.
Risk factors: Current eye inflammation (e.g., uveitis)
Medications like Vyzulta (latanoprostene bunod) can cause or worsen eye inflammation (redness and swelling). These problems might be more likely to happen if you already have eye inflammation. Talk to your prescriber if you notice eye discomfort or changes in your vision while you're using Vyzulta (latanoprostene bunod).
Risk factors: History of eye problems (e.g., not having a lens inside your eye, having a false lens in your eye) | Age-related macular degeneration (AMD) | Genetic eye problems | Other eye problems (e.g., inflammation, blocked veins in the eye) | Eye surgery | Using other medications that can cause macular edema
Medications like Vyzulta (latanoprostene bunod) can potentially cause swelling of the retina (also known as macular edema). Your risk for macula edema might be higher if you have a false lens in your eye(s). Macular edema can cause changes in vision, such as blurry vision or dull color vision. Contact your prescriber right away if you notice any changes in vision while you're using Vyzulta (latanoprostene bunod).
Risk factors: Corneal disease | Injury or damage to the surface of the eye
Eye infections can happen if the medication inside your Vyzulta (latanoprostene bunod) bottle gets contaminated with bacteria and then you use the drops in your eyes. Some people who used contaminated eye drops developed bacterial keratitis, a bacterial infection of the cornea (the protective covering on the front of the eye). It's important to wash your hands before each time you use Vyzulta (latanoprostene bunod). Be careful not to touch the dropper tip with your hands, to your eye, or to any other surface.
Vyzulta (latanoprostene bunod) contains a preservative called benzalkonium chloride. This preservative can be absorbed by soft contact lenses and cause damage to the lenses. Take out your soft contact lenses each time before you place Vyzulta (latanoprostene bunod) drops into your eye(s). Wait at least 15 minutes after your dose before putting your contacts back in.
The typical dose is 1 drop in the affected eye(s) once a day in the evening.
Lowering pressure in the eye in people with ocular hypertension (high pressure in the eye) or open-angle glaucoma
High pressure in the eye caused by ocular hypertension (high pressure inside the eye) or open-angle glaucoma (the most common type of glaucoma)
Fluid build-up in the eye (ocular hypertension)
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
Ahn, J., et al. (2021). Binding affinity of benzalkonium chloride on contact lens surfaces and the effects on their physical properties. Colloids and Surfaces B: Biointerfaces.
American Academy of Ophthalmology. (2020). Retina.
American Optometric Association. (n.d.). Ocular hypertension.
Bausch & Lomb Incorporated. (2024). Vyzulta- latanoprostene bunod solution/ drops [package insert]. DailyMed.
Centers for Medicare & Medicaid Services. (2015). Pharmacy auditing and dispensing job aid: Billing other dosage forms.
Harasymowucz, P., et al. (2022). Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: A systematic literature review and a network meta-analysis. British Journal of Ophthalmology.
Hu, C. X., et al. (2014). What do patients with glaucoma see? Visual symptoms reported by patients with glaucoma. The American Journal of the Medical Sciences.
Kaufman, P. L. (2017). Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension. Expert Opinion on Pharmacotherapy.
Merchel Piovesan Pereira, B., et al. (2019). Benzalkonium chlorides: Uses, regulatory status, and microbial resistance. Applied and Environmental Microbiology.
National Eye Institute. (2021). How to put in eye drops.
National Eye Institute. (2023). Macular edema.
National Eye Institute. (n.d.). Parts of the eye.
Schlessinger, D. I., et al. (2023). Biochemistry, melanin. StatPearls.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.